- Home
- BGMS vs CLDI Comparison
BGMS vs CLDI Comparison
Compare BGMS & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGMS | CLDI |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BGMS | CLDI |
|---|---|---|
| Price | $0.91 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.3K | ★ 269.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $137.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.22 |
| 52 Week High | $6.70 | $7.32 |
Technical Indicators
Market Signals| Indicator | BGMS | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 18.93 |
| Support Level | $0.74 | $0.22 |
| Resistance Level | $1.12 | $0.90 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 54.96 | 0.53 |
Price Performance
Historical ComparisonAbout BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.